share_log

上海医药:决定终止三个研发项目的临床试验及后续开发

SH PHARMA: Decided to terminate clinical trials and subsequent development of three research projects.

Breakings ·  Jan 1 18:54

SH PHARMA announced that based on a comprehensive assessment of factors such as the future market value of research projects, business synergy, and subsequent development investments, it has decided to terminate the clinical trials and subsequent development of three research projects: I001-B (USA), I022 (USA), and C012 (USA). Among them, I001-B (USA) and I022 (USA) are in Phase II of clinical trials in the USA, and C012 (USA) has received FDA permission for Phase I clinical trials. The company stated that the termination of the clinical trials and subsequent development will not have a significant impact on the company's performance. The company will continue to place emphasis on Pharmaceutical research and development while strictly controlling R&D costs, but R&D of new drugs carries high risks, long cycles, and many uncertainties.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment